Vycor Medical, Inc. Announces Leadership Change, Appoints New Chief Executive Officer
July 02 2012 - 2:00PM
Marketwired
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO) today announces that
Richard P. Denness will be joining Vycor as its new Chief Executive
Officer, replacing Ken Coviello. During this transition period, Ken
will retain a role with the company on a consultancy basis. Since
the acquisitions of NovaVision, Inc. and Sight Science Limited,
Vycor has become an international group of greater complexity with
several businesses. Richard Denness is a healthcare executive with
global experience who has held senior management positions at UCB,
Inc., Schwarz Pharma US, Schering-Plough and IVAX Corporation.
Kenneth T. Coviello, the current Chief Executive Officer of
Vycor, has played a crucial role in the development of Vycor and
its VBAS product line, which has been achieving excellent growth
and progress in US and international markets. Ken had indicated to
the Board a desire to pursue personal interests and pass the role
on to a new executive to take Vycor forward to the next level, once
an appropriate successor could be found.
Adrian Liddell, Chairman of Vycor, stated: "We are delighted to
welcome Richard as the new CEO of Vycor; Richard has the
operations, strategic, and management leadership experience
required to run a fast moving healthcare company such as Vycor. We
believe he is ideally equipped to take Vycor forward into the next
exciting phase of its development. At the same time, Vycor owes a
huge debt of gratitude to Ken, who has led the company from
inception and we wish him all the best with his future plans."
About Vycor Medical, Inc.
With corporate headquarters in Boca Raton, FL, Vycor Medical,
Inc. (OTCBB: VYCO) is a medical device company committed to making
neurological brain, spinal and other surgical procedures safer and
more effective. The company's flagship, Patent Pending ViewSite™
Surgical Access Systems represent an exciting new minimally
invasive access and retraction system that holds the potential for
speedier, safer and more economical brain, spinal and other
surgeries and a quicker patient discharge. Vycor's innovative
medical instruments are designed to optimize neurosurgical site
access, reduce patient risk, accelerate recovery, and add tangible
value to the professional medical community. Vycor is ISO
13485:2003 compliant, has FDA 510(K) clearance for brain and spine
surgeries, and CE Marking and HPB licensing in Canada.
Vycor Medical's subsidiary, NovaVision, Inc., researches,
develops and provides science-driven vision-based neurostimulation
therapy and other medical technologies that help to improve sight
in patients with neurological vision impairments. The company's
proprietary, Visual Restoration Therapy (VRT) platform is
clinically supported to improve lost vision resulting from stroke,
traumatic brain injury ("TBI"), or other acquired brain injury, and
has been 510(K) cleared to be marketed in the US by the FDA. VRT
can be prescribed by any ophthalmologist, optometrist, neurologist
or physiatrist. NovaVision, through its subsidiary Sight Science,
also provides Neuro-Eye Therapy (NeET), aimed at increasing visual
sensitivity deep within the field defect. NovaVision also provides
a fully portable and ADA-compliant Head Mounted Perimeter (HMP™)
which aids in the detection and measurement of visual field
deficits.
For the latest information on the company, including media and
other coverage, and to learn more, please go online at
www.vycormedical.com or www.novavision.com.
Safe Harbor Statement
Information in this document constitute
forward-looking statements or statements which may be deemed or
construed to be forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995.
The words "forecast," "anticipate," "estimate,"
"project," "intend," "expect," "should," "believe," and similar expressions are intended to identify
forward-looking statements. These forward-looking statements
involve, and are subject to known and unknown risks, uncertainties
and other factors which could cause Vycor Medical's actual results,
performance (financial or operating) or achievements to differ from
the future results, performance (financial or operating) or
achievements expressed or implied by such forward-looking
statements. The risks, uncertainties and other factors are more
fully discussed in Vycor Medical's filings with the U.S. Securities
and Exchange Commission. All forward-looking statements
attributable to Vycor Medical herein are expressly qualified in
their entirety by the above-mentioned cautionary statement. Vycor
Medical disclaims any obligation to update forward-looking
statements contained in this estimate, except as may be required by
law.
Lenny Sorin Vycor Medical, Inc. 561-558-2000 Email Contact
Vycor Medical (QB) (USOTC:VYCO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vycor Medical (QB) (USOTC:VYCO)
Historical Stock Chart
From Sep 2023 to Sep 2024